Glaxo’s Ebola Vaccine to Be Tested for Safety in Humans

U.S. scientists will begin enrolling patients next week in safety trials of GlaxoSmithKline Plc’s experimental Ebola vaccine as the death toll from the disease rises in West Africa.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.